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The HIV-TB-associated immune reconstitution inflammatory syndrome (TB-IRIS) can
complicate combined treatments for HIV-1 and TB. Little is known about tissue damage
in TB-IRIS. Matrix metalloproteinases (MMPs) degrade components of the extracellular
matrix and consequently may play a role in such immunopathology. Here we investi-
gated the involvement of MMPs in TB-IRIS. We determined MMP transcript abundance
and secreted protein in Mycobacterium tuberculosis stimulated PBMCs from 22 TB-IRIS
patients and 22 non-IRIS controls. We also measured MMP protein levels in correspond-
ing serum and the effect of prednisone—which reduces the duration of symptoms in IRIS
patients — or placebo treatment on MMP transcript and circulating MMP protein levels.
PBMCs from TB-IRIS had increased MMP-1, -3, -7, and -10 transcript levels when com-
pared with those of controls at either 6 or 24 h. Similarly, MMP-1, -3, -7, and -10 protein
secretion in stimulated cultures was higher in TB-IRIS than in controls. Serum MMP-7
concentration was elevated in TB-IRIS and 2 weeks of corticosteroid therapy decreased
this level, although not significantly. TB-IRIS is associated with a distinct pattern of MMP
gene and protein activation. Modulation of dysregulated MMP activity may represent a
novel therapeutic approach to alleviate TB-IRIS in HIV-TB patients undergoing treatment.
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Introduction
The introduction of antiretroviral treatment (ART) has been asso-
ciated with dramatic decreases in mortality and morbidity asso-
ciated with human immunodeficiency (HIV-1) infection [1]. ART
suppresses viral replication, which permits both quantitative and
functional reconstitution of the immune system, which is associ-
ated with the restoration of pathogen-specific immune responses.
While integration of anti-TB and ART therapies is associated with
clinical improvement in most patients, HIV-TB associated immune
reconstitution inflammatory syndrome (TB-IRIS) may occur in a
subset of these patients [2].
TB-IRIS is best recognized as a paradoxical immune-mediated
deterioration in patients diagnosed with TB who are responding to
anti-TB treatment but develop subsequent clinical deterioration on
initiation of ART [2]. The condition has been reported in 8–43% of
patients commencing ART while on TB treatment. Mortality due
to TB-IRIS averages 3.2%, and morbidity is much more frequent
being a major cause of hospitalization [3]. Characteristic features
of the condition include swelling and suppuration of lymph nodes,
chest x-ray infiltration with cavitation, and formation of tissue
abscess [4]. Central to these features is immune-mediated tis-
sue destruction and breakdown of the normal extracellular matrix
(ECM) structure.
Matrix metalloproteinases (MMPs) are zinc-dependent
endopeptidases capable of degrading all components of the ECM
including fibrillar type I collagen, a key structural fibril that is
otherwise, highly resistant to enzymatic degradation [5, 6]. The
lung matrix is supported by these highly stable fibrillar collagens
[7, 8]. MMPs perform multiple roles including tissue remodeling,
repair, and modulation of immune responses [9–12]. In healthy
tissues, MMPs are rarely expressed: their biological activity is
tightly regulated by various mechanisms. Activated MMPs are reg-
ulated by endogenous inhibitors, called tissue inhibitors of metal-
loproteinases (TIMPs) that bind latent and active forms of MMPs
[13,14].
Excessive MMP production has been reported in diverse
inflammatory conditions such as cancer, chronic obstructive pul-
monary disease, sarcoidosis, interstitial lung disease, arthritis,
and atherosclerosis. Advanced pulmonary TB is associated with
a locally destructive process of cavitation, which plays an impor-
tant role in transmission of the disease, but whose pathogenesis
remains incompletely understood [10,15,16]. Emerging data asso-
ciates MMP activity with pathology in TB. In recent work, Volkman
et al. have demonstrated that disruption of MMP-9 function atten-
uated granuloma formation and bacterial growth, suggesting that
targeting of MMP-9 production could be a promising target for
adjunctive immunotherapy [17]. We hypothesized that dysregu-
latedMMP activitymay play a critical role in the immunopathology
and tissue destruction in TB-IRIS. To investigate this hypothesis,
we comprehensively analyzed MMP gene expression and protein
secretion in patients who developed paradoxical TB-IRIS and sim-
ilar non-IRIS control patients.
Results
Baseline characteristics of participants
Participants with suspected TB-IRIS were recruited at GF Jooste
Hospital, Cape Town, South Africa between March 2005 and
December 2006. The 22 TB-IRIS and 22 non-IRIS participants
included in the cross-sectional analysis have been previously
described [18]. There were no significant differences in the age,
gender, and baseline CD4 counts between the two clinical groups.
The median time from starting TB treatment, to commencement
of combination ART, reporting of TB-IRIS or sample collection was
similar in both groups of participants (Supporting Information
Table 1).
A second group of participants originated from a randomized
placebo-controlled trial (RCT) of prednisone and placebo-treated
TB-IRIS patients that has been previously reported [19]. Support-
ing Information Table 2 shows a summary of the baseline and
clinical characteristics for the subset of RCT patients analyzed for
the current study. There were no significant differences in gender
or baseline CD4 counts between the prednisone-treated (n = 16)
and placebo-treated (n = 12) patient groups. The proportion of
participants with previous TB infection, extrapulmonary TB, and
IRIS manifestation was similar between the two groups, although
a marginal difference (p = 0.04) was observed in the median days
of TB treatment prior to ART.
Transcript abundance of MMP genes in TB-IRIS and
non-IRIS participants
Relative transcript abundance was assessed by normalizing the
cycle threshold (Ct) of the MMP gene of interest with that of the
endogenous control, β-Actin. A lower delta Ct value indicates a
more abundant transcript and vice versa. Stimulation of PBMC
by Mycobacterium tuberculosis increased the transcript abundance
for multiple MMPs in both the TB-IRIS and non-IRIS groups. At
6 h, MMP-3, -7, and -10 transcripts were significantly more abun-
dant (p ≤ 0.05) in the unstimulated controls; after correcting
for multiple comparisons, only MMP-3 transcript remained higher
(pcorr = 0.01) in the unstimulated 6 h non-IRIS cultures (results
not shown). Upon stimulation with M. tuberculosis for 6 h, several
of the MMP transcripts including MMP-1, MMP-3, MMP-7, and
MMP-10 (pcorr ≤ 0.05) increased in abundance in both TB-IRIS
and non-IRIS patients when compared with those of unstimulated
cultures (Supporting Information Table 3).
At 24 h, no significant differences were noted in the tran-
script abundance of unstimulated IRIS versus non-IRIS PBMC cul-
tures (data not shown). However, after 24 h of stimulation with
M. tuberculosis, MMP-1, MMP-7, and MMP-10 transcripts were
observed to be significantly higher in the PBMC cultures of TB-IRIS
as compared with those of non-IRIS patients (pcorr = 0.02, pcorr =
0.05 and p= 0.01, respectively) (Supporting Information Table 3).
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Fold induction analysis of MMP genes
To compare the differences of gene induction between IRIS
and non-IRIS, fold induction was determined using the delta
delta () Ct method and values normalized by a Log-10
transformation and analysis performed by an unpaired t-test.
MMP-1, -3, and -12 tended to be more induced in TB-IRIS at
either 6 or 24 h. MMP-7 and MMP-10 were consistently higher at
both 6 and 24 h in TB-IRIS patients before correcting for multiple
comparisons. After Bonferroni correction, MMP gene induction
was significantly higher in TB-IRIS than in non-IRIS controls
for MMP-3, and MMP-10 at 6 h (pcorr ≤ 0.05), while at 24 h,
significant differences existed between TB-IRIS and non-IRIS
participants for MMP-7 (pcorr ≤ 0.001). In contrast, the RNA levels
of MMP-2, MMP-8, TIMP-2, and MMP-11 tended to be suppressed
by M. tuberculosis stimulation at either 6 or 24 h in both groups
(Fig. 1).
MMP protein secretion into PBMC culture
supernatants
MMP protein secretion into the corresponding 24 h PBMC
culture supernatants harvested from M. tuberculosis stimulated
PBMCs was analyzed by luminex and ELISA assays. The MMP
concentrations were background subtracted, i.e. the difference
between stimulated and unstimulated cultures was calculated
and analyzed (Fig. 2). After correction for multiple comparisons,
concentrations of MMP-1, -3, -7, and -10 in the PBMC culture
supernatants were found to be significantly higher in the TB-IRIS
compared with those from controls (pcorr ≤ 0.05). Although
MMP-9 was detected in abundance in these cultures, the levels
of this MMP did not differ between the two clinical groups.
While TIMP-2 was detected at the transcript level (Supporting
Information Table 1), no TIMP-2 protein was detected in these
cultures. MMP-9 enzymatic activity on gelatin was determined by
zymography (Supporting Information Fig. 1). An abundance of
active MMP-9 was observed in both TB-IRIS and non-IRIS groups
and this tended to relate well to the MMP-9 levels measured by
luminex.
Correlation of MMP mRNA transcripts
To assess if there were any relationships between different MMP
transcripts, we correlated the fold induction of theMMPswith each
other. The fold induction values forMMP-1 andMMP-10 transcript
were highly and significantly correlated at both 6 and 24 h in
both clinical groups (r = 0.64–0.89 and p ≤ 0.001). Correlation
between MMP-1 and MMP-7 was significant only in the IRIS group
at both 6 and 24 h (r = 0.458 and 0.613, p ≤ 0.04). Correlation
between MMP-3 and MMP-10 was significant only at 6 h in the
IRIS group (r= 0.602, p= 0.018). No other significant correlations
were noted.
Correlation between MMP transcript and
corresponding secreted cell culture supernatant
protein
To assess the relationship between MMP transcript and protein
secreted into the corresponding supernatant, we correlated the
MMP transcript with the 24 h supernatants (Spearman’s correla-
tion). As expected, there was an inverse correlation between the
24 h delta CT (mRNA transcript abundance) and secreted protein
for MMP-1, MMP-3, andMMP-7. A strong negative correlation was
observed between 6 hmRNA (stimulated) and secreted protein for
MMP-3 (r = −0.626, p ≤ 0.0002). No significant correlations were
noted for any of the other MMPs.
Analysis of MMP concentration in serum samples
To determine whether the increased MMP expression and secre-
tion detected in vitro was reflected in vivo, we analyzed circulating
MMPs in corresponding serum samples of the TB-IRIS and control
participants. MMP protein levels in the serum of 22 TB-IRIS and
22 controls were measured by luminex for those analytes shown
to be significantly different between IRIS and non-IRIS in the cell
culture supernatants. MMP-7 was significantly higher in the serum
of TB-IRIS compared to controls (pcorr = 0.005, Fig. 3).
No other significant differences were noted in the concentra-
tions of the circulating proteins between TB-IRIS and control par-
ticipants for the other MMPs.
Effect of corticosteroid therapy on gene expression
and serum levels in TB-IRIS patients
Prednisone therapy has been shown to improve clinical outcomes
in patients presenting with paradoxical TB-IRIS [19]. MMP-1,
MMP-3, MMP-7, and MMP-10 gene expression was analyzed by
quantitative RT-PCR in M. tuberculosis stimulated PBMCs from 16
TB-IRIS participants treated with prednisone therapy compared
with 12 patients who were placebo treated over 4 weeks of pred-
nisone versus placebo treatment. Prednisone significantly sup-
pressed MMP-7 gene expression over the treatment course (pcorr =
0.019). On the other hand, MMP-1 and MMP-3 genes were unaf-
fected by corticosteroid or placebo treatment over the treatment
course. Finally, we analyzed circulating MMP concentrations in
the serum of TB-IRIS participants over the 4 weeks of treatment.
Prednisone tended to suppress circulating MMP-7 concentrations
within the first 2 weeks in the prednisone group compared with
those after placebo treatment, although this was not significant
(p = 0.2) (Fig. 4).
Discussion
We performed a study to investigate the role of tissue degrading
MMP enzymes in patients who developed paradoxical TB-IRIS.
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Figure 1. Patients who develop TB-IRIS express increased levels of MMPs. Log-fold induction of MMP genes by heat killed MTB in PBMCs from
TB-IRIS at the time of TB-IRIS and non-TB-IRIS control participants who had received a similar duration of antitubercular and antiretroviral
therapy. PBMCs from 22 TB-IRIS and 22 controls were cultured in the presence or absence of heat killed H37Rv M. tuberculosis for 6 and 24 h. The
PBMCs were lysed and mRNA analysis was performed by quantitative RT-PCR. Transcript abundance was calculated by subtracting the Ct β-Actin
from the CT of the MMP gene of interest. Fold induction was calculated by the Ct method and values normalized by Log-10 transformation.
Fold induction analysis between IRIS and non-IRIS was performed by unpaired t-test. At 6 h, after Bonferroni correction, MMP gene induction was
significantly higher in TB-IRIS than in controls for MMP-3, MMP-7, and MMP-10 (pcorr ≤ 0.05). At 24 h, significant upregulation existed between
TB-IRIS and non-IRIS participants for MMP-1, MMP-7, MMP-10, and MMP-12. MMP-12 was undetectable in 6 h cultures. In this figure, the black bars
represent TB-IRIS patients while open bars represent non-IRIS controls. Data are shown as median + IQR of 22 TB-IRIS versus 22 non-IRIS control
patients for each MMP analyzed (as represented by each panel).
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Figure 2. Increased MMP concentrations in PBMC culture supernatants from IRIS patients MMP concentrations were assayed in the PBMC culture
supernatants arising from 20 TB-IRIS at the time of TB-IRIS and 20 non-TB-IRIS participants after a similar duration of antitubercular and
antiretroviral therapy. The MMP concentrations shown are background subtracted, values being the (delta) difference between stimulated and
unstimulated cultures. The delta MMP concentrations of IRIS versus non-IRIS was compared using the Mann–Whitney test. Concentrations of
MMP-1, -3, -7, and -10 were found to be significantly higher in the TB-IRIS compared with controls (pcorr = 0.05). Closed circles represent TB-IRIS
patients while open circles represent the non-IRIS controls. Each symbol represents an individual patient and bars represent median values with
only significant p-values (p ≤ 0.0.5) shown on the relevant panels.
TB-IRIS is characterized by immune-mediated tissue damage, and
therefore MMPs may play a part in this pathology [7, 15, 20, 21].
Our findings show thatM. tuberculosis stimulation of PBMCs differ-
entially increased the transcript levels for MMP-1, MMP-7, MMP-
10, and TIMP-1 genes in paradoxical TB-IRIS participants in 24 h
cultures (pcorr ≤ 0.05) compared with non-IRIS controls. Fold
induction was significantly higher in TB-IRIS than in controls for
MMP-3 at 6 h, while in the 24 h cultures MMP-1 and MMP-12
were differentially induced in TB-IRIS. MMP-7 and MMP-10 were
differentially induced in TB-IRIS at both 6 and 24 h. There was
consistency between gene expression and supernatant results with
higher MMP protein levels observed in the cell culture super-
natants forMMP-1, -3, -7, and -10 that weremore highly expressed
in TB-IRIS. The upregulation of MMP-1, -3, -7, and -10 by
M. tuberculosis is consistent with previous reports in primary
human macrophages, monocytes, and PBMC [22]. MMP-7 is
expressed inmacrophageswithin TB granulomas [15,22]. Analysis
of serum samples showed MMP-7 and TIMP-1 protein levels to be
higher in vivo for TB-IRIS compared with those in controls (Fig. 3).
Prednisone has been shown to improve clinical outcomes in TB-
IRIS patients [19]. By contrast, the transcript levels of MMP-2, -8,
-11, and TIMP2 were decreased by restimulation with M. tubercu-
losis. MMP-2 levels in the corresponding cultures were, in many
cases, suppressed by the presence of M. tuberculosis and TIMP-2
protein was undetectable. These effects did not differ between TB-
IRIS and non-IRIS participants and thus we attribute the findings
to a general effect of M. tuberculosis antigens rather than specific
for TB-IRIS.
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Figure 3. MMP concentrations in the serum of
patients. MMP protein levels in the serum samples
of 22 TB-IRIS at the time of TB-IRIS and 22 non-
IRIS controls who had received a similar duration of
antiretroviral therapy were measured by luminex
for those analytes shown to be significantly dif-
ferent between IRIS and non-IRIS in the cell cul-
ture supernatants. MMP protein levels between IRIS
and non-IRIS serum samples were compared using
the Mann–Whitney test. MMP-7 protein was signifi-
cantly higher in serum samples from TB-IRIS when
compared with controls (pcorr = 0.005). The concen-
tration of TIMP-1 protein was also observed to be
significantly higher in TB-IRIS (pcorr = 0.013). In this
figure, open circles represent the TB-IRIS patients
while the closed circles represent the non-IRIS con-
trols. Each symbol represents an individual patient
and the bars representmedian values with only sta-
tistically significant p-values (p ≤ 0.05) shown.
The involvement of MMPs in lung biology and in tissue degra-
dation in pulmonary TB has been reported previously [5, 20].
However, ours is the first study to investigate the involvement
of these tissue-degrading enzymes in paradoxical TB-IRIS. Our
findings corroborate related findings on analysis of gene expres-
sion and secretion following M. tuberculosis stimulation of human
microglia in a cellular model of CNS TB [23]. Our findings suggest
that MMPs are involved in the immunopathogenesis in TB-IRIS
and that infection with MTB promotes a tissue-damaging pheno-
type that is evident in TB-IRIS [2].
While MMP-9 was highly expressed in the patients we stud-
ied, there was no difference in the levels of this MMP in both
the mRNA and secreted protein between TB-IRIS and non-IRIS
participants. Analysis of MMP-9 enzymatic activity by zymogra-
phy showed an abundance of active MMP-9 in both TB-IRIS and
non-IRIS groups and this tended to relate well to the MMP-9 lev-
els measured by luminex. MMP-9 has previously been implicated
in TB immunopathology [9, 24]. More recently, MMP-9 has been
implicated in the regulation of monocyte recruitment in granu-
loma formation and bacterial growth in the M. marinum model
of infection in zebrafish [17]. We did not demonstrate divergent
MMP-9 gene expression or secretion between IRIS and non-IRIS
patients in these studies. Thus, while our data support that MMP-9
is associated with the pathogenesis of TB, it does not appear to be
specifically associated with the immunopathology that is evident
in TB-IRIS.
MMP-7 associated with TB-IRIS and was suppressed by pred-
nisone treatment. MMP-7 may act as a regulator of the immune
response in this condition in addition to potentially cleaving fibrils
of the ECM [25]. MMP-7 is a multifunctional MMP that is required
for activation of defensins [26]. For example, MMP-7 regulates
neutrophil egression into the lung by cleaving syndecan-1 to then
C© 2013 The Authors. European Journal of Immunology published
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Figure 4. Prednisone tends to suppress circulating MMP concentration
in TB-IRIS patients. To assess the effect of steroid therapy on circulating
MMP protein concentrations in vivo, (in serum samples) 14 prednisone-
treated and 8 placebo-treated TB-IRIS participants were assessed for
those MMPs that were higher in IRIS in cell culture supernatants, i.e.
MMP-1, MMP-3, and MMP-7. MMP concentrations for each treatment
group at the 2- and 4-week time points were analyzed by the Wilcoxon
matched-pairs signed rank test. Prednisone tended to suppress MMP-7
concentrations after 2 weeks of therapy although this did not reach sta-
tistical significance after correcting for multiple comparisons (p = 0.2).
In this figure, open circles represent the placebo-treated patients while
closed circles represent the steroid (prednisone) treated IRIS patients.
Each symbol represents an individual patient.
generate a chemotactic gradient [27] and can also release pro-
TNF-α from the cell surface [28]. In other studies, MMP-7 has
been shown to regulate the lung localization of dendritic cells to
limit inflammation and inhibit fibrosis [29]. MMP-7 activity has
also been previously implicated in the pathogenesis of aberrant
lung remodeling in pulmonary fibrosis [30].
TIMPs are known to downregulate MMP activity by binding
to latent and active forms of MMPs. While TIMPs are constitu-
tively expressed in many tissue fluids, including CSF [31], the
peripheral measurement of these inhibitors may not always reflect
tissue effects [32]. This may explain our inconsistent findings for
TIMPs in this study. TIMP genes were generally not regulated by
M. tuberculosis at mRNA and cell culture supernatant levels,
although TIMP-1 was found to be elevated in the serum of
TB-IRIS participants.
We acknowledge some limitations to our study. It is important
to note that the mechanisms associated with regulating the poten-
tially destructive nature of MMPs such as binding of active MMPs
to their endogenous inhibitors may complicate the quantification
of these enzymes in biological samples. Endogenous inhibitors
including α-macroglobulin and other TIMPs exert their effect in
vivo by trapping active MMPs [33]. Jung and others have demon-
strated the importance of blood sample collection for MMP-related
analyses and that MMPs and TIMPs concentrations differ between
plasma and serum in relation to coagulation and fibrolytic path-
ways [34, 35]. Anticoagulants have been shown to interfere with
Figure 5. Summary of study findings. While MMP-1, MMP-7, and
MMP-10 were consistently elevated in TB-IRIS patients according to
experimental circumstances, MMP-7 was the only one that remained
elevated in all circumstances, i.e. both in vitro and in vivo. Furthermore,
although this did not reach statistical significance, MMP-7 was the only
MMP that tended to be modulated by prednisone therapy.
MMP activity and so the use of serum may be unreliable for some
MMPs. In particular, MMP-1, and MMP-3 are released during
blood clotting [34]. Thus, the use of serum as opposed to plasma
samples may have obscured some differences in these proteases.
Themeasurement ofMMPs in systemic circulation, i.e. in the blood
compartment as opposed to the site of disease may only partially
reflect production at the site of disease and in the lung [26,36]. Dif-
ferences in MMP expression between individual TB-IRIS patients
may be attributed to the heterogeneity in the TB-IRIS patient
cohort. We acknowledge that our sample size was relatively small
and this may have accounted for some borderline significance of
some of the reported findings. Further work may be needed to
explore these findings in a larger sample size before a clinical trial
of MMP inhibitors could be considered in TB-IRIS patients.
In summary, our studies show that stimulation with M. tuber-
culosis differentially upregulates multiple MMPs in TB-IRIS partic-
ipants, summarized in Fig. 5. MMP-7 was consistently expressed
at increased levels in participants with TB-IRIS and was sup-
pressed by prednisone. As corticosteroids have multiple delete-
rious immunological effects and may be harmful in the context of
drug-resistant TB, more specific immunomodulatory approaches
are needed in TB-IRIS. Dysregulated MMP activity may repre-
sent a therapeutic target to reduce immunopathology without
causing steroid-related immunocompromise. Our findings indi-
cate involvement of MMPs in the immunopathology of paradoxi-
cal TB-IRIS, which may present a potential therapeutic target in
modulating this condition.
Materials and methods
Patient enrolment and study design
Participants were recruited at GF Jooste Hospital and at the
Ubuntu Clinic, Site B Khayelitsha, in Cape Town, South Africa
C© 2013 The Authors. European Journal of Immunology published
by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
134 Rebecca Tadokera et al. Eur. J. Immunol. 2014. 44: 127–136
betweenMarch 2005 and December 2007 to two prospective stud-
ies whose designs have been previously reported [19,37]. TB cases
were prescribed 6months first line therapy of isoniazid, rifampicin,
pyrazinamide, and ethambutol (HRZE) for 2 months followed by
HR for 4 months (2HRZE/4HR). Patients with previous episodes
of TB had streptomycin added to the regimen. All patients were
prescribed an ART combination of stavudine (d4T), lamivudine
(3TC), and either efavirenz (EFZ) or nevirapine (NVP). Patients
suspected or confirmed to have rifampicin or multidrug resistant
TB were excluded from the study. Patients were prospectively
enrolled into the study and followed up for 12 weeks. Patients
were over 18 years of age, not pregnant and ART naive. At entry
into these studies, a clinical diagnostic work-up was performed to
exclude alternative diagnosis for clinical deterioration. The Uni-
versity of Cape Town Research Ethics committee approved these
studies (REC references 337/2004 and 173/2005). All participants
provided written informed consent for enrolment into the study.
Cross-sectional analysis of paradoxical TB-IRIS and
non-IRIS patients
For the cross-sectional case-control analysis, TB-IRIS patients were
selected from participants who had a confirmed diagnosis of para-
doxical TB-IRIS based on the published International Network
for the Study of HIV-associated IRIS (INSHI) consensus case def-
inition [2] that has been independently validated [38–40]. The
study design, patient selection criteria, and treatment regimens
have been previously described [18]. In this analysis, we selected
22 cases of patients (of 32 available) diagnosed with paradoxical
TB-IRIS and compared these with 22 non-IRIS control patients
who were treated for HIV-associated tuberculosis and had simi-
lar baseline CD4 count and duration of ART but did not develop
TB-IRIS. We included patients who (i) were ART naive, (ii) had
microbiologically confirmed tuberculosis, or conformed to WHO
clinical definitions for HIV-associated TB with response to treat-
ment (iii) had no evidence of Rifampicin resistance or MDR, (iv)
were diagnosed with paradoxical TB-IRIS based on a validated
consensus case definition [2].
Analysis of randomized placebo-controlled trial (RCT)
paradoxical TB-IRIS patients
We have previously described the study design for the RCT of
prednisone versus placebo for the management of paradoxical
TB-IRIS [19]. Patients presenting with new or recurrent TB symp-
toms on ART and at least one of the following TB-IRIS manifes-
tations were enrolled: infiltrate on chest radiograph, enlarging
lymph node(s), serous effusion, or cold abscess. Exclusion criteria
included life-threatening TB-IRIS (mainly neurological involve-
ment). Study medication was prednisone or matching placebo.
Participants received study medication for 4 weeks: 1.5 mg/kg
per day for 2 weeks followed by 0.75 mg/kg per day for 2 weeks.
Blood for MMP analysis was drawn at week 0, 2, and 4.
Blood processing and cell culture
PBMC were isolated by Ficoll processing of heparinized blood and
were plated at 2.5 × 106/well. These were then restimulated with
heat killed H37Rv M. tuberculosis (prepared in-house from log
phase cultures) for 6 or 24 h at a multiplicity of infection of 1:1.
After incubation, PBMCs were harvested and lysed for RNA extrac-
tion. Cell lysates at 6 and 24 h time points were stored for RNA
analysis and the 24 h PBMC culture supernatants were cryopre-
served at −80◦C. Serum was also collected and cryopreserved at
−80◦C until further analysis.
Quantitative RT-PCR
mRNAwas extracted from PBMC lysates using the RNeasy Mini Kit
Spin Protocol (Qiagen, Valencia, CA, USA) as per manufacturer’s
recommendations and was cryopreserved at −80◦C until further
analysis. Primers and probes were purchased from Applied Biosys-
tems as inventoried TaqMan R© Gene Expression Assays (Applied
Biosystems, Qiagen). The following were the Assay IDs for each
of the genes: MMP-1: Hs00899658 m1, MMP-2 Hs00234422,
MMP-3: Hs00968308 m1, MMP-7: Hs01042795 m1, MMP-8:
Hs01029057 m1, MMP-9: Hs00957555 m1, MMP-10:
Hs00233987 m1, MMP-11: Hs00968295 m1; MMP-12:
Hs00159178 m1, MMP-13: Hs00233992 m1, TIMP-1:
Hs99999139 m1, TIMP-2: Hs00234278 m1. The TaqMan R©
RNA-Ct 1 Step kit was used in these assays.
Relative transcript abundance was assessed by subtracting
the cycle threshold (Ct) of the gene of interest from the cycle
threshold of the endogenous control, β-Actin to obtain the differ-
ence in thresholds ( Ct). A lower delta Ct value indicates more
abundant transcript. Fold induction was used to obtain a relative
measure of gene induction by MTB and was determined using the
Ct method. Ct was calculated by subtracting the Ct of
the unstimulated sample from that of the stimulated sample and
adding the resulting value to the mathematical equation 2−Ct
followed to obtain a fold induction/repression of the gene. Values
were Log-10 transformed to normalize data before analysis.
Analysis of PBMC culture supernatant and serum
samples
Multiplex assays for MMPwere performed on PBMC culture super-
natants and serum samples using human MMP multianalyte pro-
filing base kit reagents and Protocol (Human Fluorokine MAP
Base Kit, MMP Panel, Cat number LMP000) on the Bio-Rad Bio-
plex 200 platform. This method detects MMP pro-enzyme content.
For MMP-9 analysis, cell culture supernatants were diluted 1:100
before analysis. MMP-10 was measured using the R&D Quan-
tikine ELISA kit (R&D Systems, Cat. number DM1000) which
measures human pro-MMP-10 protein with a limit of detection
of 4.13 pg/mL. TIMP-1 and TIMP-2 were measured using the
R&D Duoset R© ELISA Development System (R&D Systems, Cat.
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numbers: DY970, DY971). For the TIMP-1 and TIMP-2 assays, cell
culture supernatant and serum samples were diluted 1:50. For all
the cell culture supernatants, the concentrations were background
subtracted before analysis and these results are reported.
Statistical analysis
Data analysis was performed using GraphPad Prism Version 5.0a.
The normality of the data was assessed by the D’Agostino &
Pearson test. Medians are quoted ± interquartile range (IQR)
and means ± SD. Paired parametric data was analyzed by Stu-
dent’s paired t-test, or repeated measures one-way analysis of
variance (ANOVA). Paired nonparametric variables were analyzed
by the Wilcoxon signed rank test or Friedman test. RCT samples
were analyzed by Kruskal–Wallis test with no posttest correction.
Unpaired parametric variables were assessed using the unpaired
t-test for parametric data while the Mann–Whitney U test was
used for analysis of unpaired nonparametric data. Corrections for
multiple comparisons were done using the Bonferroni correction,
i.e. p-values multiplied by (n-1).
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